Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Net Cash Flow for 9 consecutive years, with $114.4 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 35.62% to $114.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.9 million through Dec 2025, down 33.35% year-over-year, with the annual reading at $31.9 million for FY2025, 33.35% down from the prior year.
  • Net Cash Flow for Q4 2025 was $114.4 million at Denali Therapeutics, up from -$50.2 million in the prior quarter.
  • The five-year high for Net Cash Flow was $114.4 million in Q4 2025, with the low at -$188.5 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$15.0 million, with a median of -$3.4 million recorded in 2023.
  • The sharpest move saw Net Cash Flow soared 503.37% in 2024, then tumbled 414.87% in 2025.
  • Over 5 years, Net Cash Flow stood at -$101.1 million in 2021, then surged by 198.37% to $99.4 million in 2022, then crashed by 121.03% to -$20.9 million in 2023, then skyrocketed by 503.37% to $84.3 million in 2024, then soared by 35.62% to $114.4 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $114.4 million, -$50.2 million, and $84.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.